JASON KROPP advises emerging and growth-stage companies, venture and growth equity investors, and mature private businesses on a wide range of strategic transactions and corporate matters. His practice focuses on the life sciences, biotech, medical device, software, and e-commerce industries, where he counsels clients from formation through exit, including financings, M&A, and other mission-critical deals.
Jason represents both companies and investors in early- and late-stage venture capital and growth financings, often serving as outside general counsel to high-growth private companies. He regularly works with clients navigating complex equity structures, board and governance matters, and strategic transactions across the corporate lifecycle. Jason has advised on more than 500 private company financing transactions, resulting in more than US$32 billion of proceeds.
Jason has been recognized in the 2015–2024 editions of Chambers USA for his work in Corporate/M&A in Massachusetts, with sources describing him as “really phenomenal in the corporate and securities area” and that “he has a great temperament, he’s a great negotiator, and he keeps his cool in situations.” He was named a “Life Sciences Star” by LMG Life Sciences (2023), and as “Venture Capital Attorney of the Year” by LMG Life Sciences in 2022 and shortlisted in 2023. Jason was also recommended in the area of M&A: Middle-Market and Venture Capital and Emerging Companies in the 2018 and 2019 editions of Legal 500 United States, named a Thomson Reuters “Stand-out Lawyer” — independently rated and selected by clients, and selected by peers for inclusion in The Best Lawyers in America® for Corporate Law (2024) and Venture Capital Law (2024).
Prior to attending law school, Jason worked as a legislative and press aide in the office of U.S. Representative William Delahunt, and as a legislative intern in the office of U.S. Representative Gerry Studds.